Back to search

University of Thessaly (UTH)

The role of neurofilaments in multiple sclerosis, and their prognostic value

Abstract

dc:description

Multiple sclerosis (MS) is the commonest autoimmune disease of the central nervous system. Up to this day, no single prognostic biomarker has been consistently proven as accurate for the disease. Neurofilaments are basic structural components of neural axons that are released upon axonal damage and have gained attention in MS. In this study, neurofilament light-chain (NfL) levels were measured in the cerebrospinal fluid (CSF) of 83 MS patients at their first hospital admission. The patients were longitudinally followed up and EDSS assessments (MS disability) were performed. MSSS scores (MS severity) were also calculated. For disability, patients were allocated to a benign (EDSS≤3) and non-benign course (EDSS>3), and for severity, to benign, moderate, and severe disease courses (benign: 0–1.999, moderate: 2–6.999, severe: 7–10). NfL levels ranged between 185.8 and 24,440.0 ng/dl (median=995.8 ng/dl, mean=2032.9 ng/dl ±3107.8). The mean follow-up was 12.3 years (±6.7, 2-41 years, median=11 years). No significant association was found between NfL levels and age of onset (p = 0.858), disability (OR benign vs. non-benign: 0.916, p = 0.725), or severity (OR moderate vs. benign: 1.077, p = 0.791, OR severe vs. benign: 1.163, p = 0.642). A significant association was found between older age of onset and disability (OR benign vs. non-benign: 1.073, p = 0.005), and severity (OR moderate vs. benign: 1.063, p = 0.039, OR severe vs. benign: 1.122, p = 0.001). Additionally, a systematic review of the MEDLINE and SCOPUS databases was conducted, collecting all available studies assessing NfL levels in either CSF (98 studies) or blood (150 studies) as biomarkers in MS. The studies were widely heterogeneous, however the results show that NfL are a better marker of clinical and/or radiological disease activity within limited timeframes (1-2 years) and not longitudinally, as this study also revealed, with the strongest associations being shown with radiological parameters, and mostly gadolinium-enhancing lesions. There was a good correlation between levels in CSF and blood, though many studies reported levels in blood underneath the detection threshold. NfLs also showed potential as treatment markers, showing decreases upon treatment begin. In most examined aspects, CSF and blood levels moved in similar directions, with the only discrepancy being shown within the different subtypes, where CSF levels were higher for relapsing-remitting MS, and blood levels were higher for progressive MS. Conclusively, CSF NfL do not appear to be the ideal prognostic marker for longitudinal prognostication. More research in the extended follow-up periods beyond 1-2 years is needed to confirm our findings.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Aloizou, Athina-Maria
  • Αλοϊζου, Αθηνά-Μαρία

Subjects

dc:subject × 10

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61705

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Aloizou, Athina-Maria; Αλοϊζου, Αθηνά-Μαρία. The role of neurofilaments in multiple sclerosis, and their prognostic value. University of Thessaly (UTH), 2026. http://hdl.handle.net/10442/hedi/61705